Literature DB >> 3318599

Analysis of dose-response curves to methacholine. An approach suitable for population studies.

G O'Connor1, D Sparrow, D Taylor, M Segal, S Weiss.   

Abstract

Dose-response curves to methacholine were examined in 9 normal and 10 asthmatic volunteers to determine whether the relationship between dose and response can be adequately summarized by means of a single, continuous measure that is not censored at lower levels of bronchial responsiveness. Subjects underwent a standard methacholine challenge test. There was a strong linear relationship between percent decline FEV1 and cumulative dose methacholine. We summarized each dose-response curve by the slope of a line extending from the origin to the last data point obtained. This summary dose-response slope effectively separated asthmatic from normal subjects, and there was a greater than 3,000-fold difference between the least and most responsive subjects. There was a high degree of correlation between the dose-response slope determined by the standard methacholine challenge protocol and that determined by an abbreviated protocol currently being used to examine nonspecific airway responsiveness in a large, longitudinal study of aging. Among the participants of the latter study, there is a unimodal, skewed distribution of dose-response slope. Dose-response slope is proposed as a quantitative measure of nonspecific airway responsiveness that avoids censoring and that may be particularly useful in epidemiologic studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318599     DOI: 10.1164/ajrccm/136.6.1412

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  78 in total

1.  Mite, cat, and cockroach exposure, allergen sensitisation, and asthma in children: a case-control study of three schools.

Authors:  R Sporik; S P Squillace; J M Ingram; G Rakes; R W Honsinger; T A Platts-Mills
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

3.  Increased resting bronchial tone in normal subjects acclimatised to altitude.

Authors:  C M Wilson; S E Bakewell; M R Miller; N D Hart; R C N McMorrow; P W Barry; D J Collier; S J Watt; A J Pollard
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

4.  Comparing and combining studies of bronchial responsiveness.

Authors:  Susan Chinn
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

5.  Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms.

Authors:  J D Leuppi; S H Downs; S R Downie; G B Marks; C M Salome
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

6.  Healthy worker effect and changes in respiratory symptoms and lung function in hairdressing apprentices.

Authors:  Y Iwatsubo; M Matrat; P Brochard; J Ameille; D Choudat; F Conso; D Coulondre; R Garnier; C Hubert; F Lauzier; M C Romano; J C Pairon
Journal:  Occup Environ Med       Date:  2003-11       Impact factor: 4.402

7.  Prevalence of asthma in adults in Busselton, Western Australia.

Authors:  J K Peat; M Haby; J Spijker; G Berry; A J Woolcock
Journal:  BMJ       Date:  1992-11-28

8.  Airway hyperresponsiveness in children with sickle cell anemia.

Authors:  Joshua J Field; Janet Stocks; Fenella J Kirkham; Carol L Rosen; Dennis J Dietzen; Trisha Semon; Jane Kirkby; Pamela Bates; Sinziana Seicean; Michael R DeBaun; Susan Redline; Robert C Strunk
Journal:  Chest       Date:  2010-08-19       Impact factor: 9.410

9.  Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers.

Authors:  L Joos; L McIntyre; J Ruan; J E Connett; N R Anthonisen; T D Weir; P D Paré; A J Sandford
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 10.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.